Page last updated: 2024-12-08
ro 136680
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N-anisoyl-GABA: RN from Toxlit; structure given in first source; metabolite of aniracetam [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 155723 |
| SCHEMBL ID | 2678159 |
| MeSH ID | M0185411 |
Synonyms (24)
| Synonym |
|---|
| 4-[(4-methoxyphenyl)formamido]butanoic acid |
| 72432-14-5 |
| EN300-36177 |
| n-anisoyl-gaba |
| ro 13-6680 |
| ro 136680 |
| 4-((4-methoxybenzoyl)amino)butanoic acid |
| butanoic acid, 4-((4-methoxybenzoyl)amino)- |
| STK396197 |
| 4-{[(4-methoxyphenyl)carbonyl]amino}butanoic acid |
| 4-[(4-methoxybenzoyl)amino]butanoic acid |
| AKOS000127760 |
| ro-136680 |
| DTXSID60222721 |
| 4-(p-methoxybenzoylamino)butyric acid |
| DZTVZKSCFQIBMV-UHFFFAOYSA-N |
| SCHEMBL2678159 |
| sr-01000359716 |
| SR-01000359716-1 |
| n-anisoyl-gamma-aminobutyric acid |
| CCG-295533 |
| CS-0247258 |
| 4-[(4-methoxyphenyl)formamido]butanoicacid |
| Z85888837 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The validated method has been applied to the pharmacokinetic study after a single oral administration of aniracetam dispersible tablets to human beings." | ( Determination of aniracetam's main metabolite, N-anisoyl-GABA, in human plasma by LC-MS/MS and its application to a pharmacokinetic study. Cai, S; Wang, L, 2012) | 0.38 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The applicability and accuracy of the methods were demonstrated by the analysis of over 1000 plasma samples from two bioavailability studies in healthy volunteers." | ( Determination of aniracetam and its main metabolite, N-anisoyl-GABA, in human plasma by high-performance liquid chromatography. Guenzi, A; Zanetti, M, 1990) | 0.28 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.60
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.60) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||